Literature DB >> 31218578

Direct antiviral agents upregulate natural killer cell potential activity in chronic hepatitis C patients.

Han-Ji Jiang1, Xiao-Xiao Wang1, Bi-Fen Luo1, Xu Cong1, Qian Jin1, Hong Qin1, Hai-Ying Zhang1, Xiang-Sha Kong1, Lai Wei1, Bo Feng2.   

Abstract

Direct antiviral agents (DAAs) can eliminate hepatitis C virus rapidly and make chronic hepatitis C (CHC) curable. The changes in the innate immune system during treatment with DAAs are still in dispute. To investigate how the functions of natural killer (NK) cells change during and after treatment with DAAs in each NK cell subset. Thirteen CHC patients were treated with sofosbuvir/ledipasvir, and the expression levels of NKp46 and NKG2A were tested via flow cytometry at baseline, at 2, 4, 8 and 12 weeks during the therapy and 12 and 24 weeks after the end of treatment; expression levels were compared between CHC patients and 13 healthy controls. A redirected killing assay was used to detect the cytotoxicity of NK cells. After coculturing NK cells with JFH-Huh7 cells for 72 h, HCV RNA was tested to analyze the inhibition ability of NK cells. All patients achieved sustained virologic response. The expression of the activating receptor NKp46 was decreased first at week 8 during therapy with DAAs and then increased and normalized to levels in healthy controls after treatment with DAAs. The expression of the inhibitory receptor NKG2A was decreased during and after treatment with DAAs. Each NK cell subset has a similar changing trend during and after treatment with DAAs, although some differences can be found earlier and later. The ratio of NKp46 and NKG2A was upregulated after treatment with DAAs. CD56bright NK cells have less amplitude in the frequency ratio changes after treatment with DAAs. The coculture results showed that both the specific lysis and the inhibition of HCV replication were significantly upregulated after treatment with DAAs. DAA treatments can affect patients' NK cell function. After DAA treatments, the expression of functional markers is downregulated, but the potential activity of NK cells is upregulated. The function of NK cells is normalized to levels in healthy controls. CD56bright NK cells play an important role in this process.

Entities:  

Keywords:  Direct antiviral agents; Function; Hepatitis C virus; Innate immune system; Natural killer cells

Mesh:

Substances:

Year:  2019        PMID: 31218578     DOI: 10.1007/s10238-019-00564-9

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  6 in total

1.  Viral clearance ameliorates hematological and inflammatory markers among diabetic patients infected with hepatitis C genotype 4.

Authors:  A Abdel Moneim; H A Suleiman; B Mahmoud; D Mabrouk; M Y Zaky; B Mahmoud
Journal:  Clin Exp Med       Date:  2020-02-19       Impact factor: 3.984

2.  NK and NKT-like cells in granulomatous and fibrotic lung diseases.

Authors:  L Bergantini; P Cameli; M d'Alessandro; C Vagaggini; R M Refini; C Landi; M G Pieroni; M Spalletti; P Sestini; E Bargagli
Journal:  Clin Exp Med       Date:  2019-09-04       Impact factor: 3.984

3.  Early fibrosis regression by shear wave elastography after successful direct-acting anti-HCV therapy.

Authors:  Mohamed Ahmed Samy Kohla; Ahmed El Fayoumi; Mohamed Akl; Mervat Abdelkareem; Mahmoud Elsakhawy; Sally Waheed; Mai Abozeid
Journal:  Clin Exp Med       Date:  2019-12-02       Impact factor: 3.984

4.  Direct-acting antiviral treatment downregulates immune checkpoint inhibitor expression in patients with chronic hepatitis C.

Authors:  Laszlo Szereday; Matyas Meggyes; Timea Berki; Attila Miseta; Nelli Farkas; Judit Gervain; Alajos Par; Gabriella Par
Journal:  Clin Exp Med       Date:  2020-02-27       Impact factor: 3.984

Review 5.  Reversal of Immunity After Clearance of Chronic HCV Infection-All Reset?

Authors:  Heiner Wedemeyer; Tanvi Khera; Benedikt Strunz; Niklas K Björkström
Journal:  Front Immunol       Date:  2020-10-08       Impact factor: 7.561

Review 6.  Lymphocyte Landscape after Chronic Hepatitis C Virus (HCV) Cure: The New Normal.

Authors:  Alip Ghosh; Sara Romani; Shyam Kottilil; Bhawna Poonia
Journal:  Int J Mol Sci       Date:  2020-10-10       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.